Cassava Sciences (SAVA.US) Alzheimer's therapy late-stage trial progress approved by DSMB

Cassava Sciences (SAVA.US) announced that it has completed the third interim safety review of simufilam in an important late-stage clinical trial for Alzheimer's patients. According to the Data and Safety Monitoring Board (DSMB) pre-review meeting, Cassava Sciences is advised to continue the important Phase 3 clinical study as planned without any modifications. This latest development comes after the announcement of interim safety MRI data in October 2023, which showed that simufilam, developed by Cassava Sciences, is not associated with amyloid-related imaging abnormalities seen during treatment. Cassava Sciences is a biotech company based in Texas, USA, focused on developing innovative drugs for the treatment of Alzheimer's disease. Their main research project includes a drug called simufilam, which aims to improve cognitive abilities in Alzheimer's patients by restoring the normal structure and function of brain proteins. Cassava Sciences' clinical trials for Alzheimer's treatment have garnered widespread attention. The recent progress of simufilam in the Phase 3 clinical trial has attracted significant interest from investment firms and the medical community focused on biotech companies. The success of these trials could lead to groundbreaking advancements in the treatment of Alzheimer's disease. Benefiting from this positive news, the company's stock price has risen by over 2% in pre-market trading.